What is KROS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KROS?

P/E (TTM) is n/a and 52-week range is $9.69 to $22.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KROS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KROS?

The company profile lists revenue (TTM) near $15M, net income (TTM) near $-3.85B, EPS (TTM) near $-3.70 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Keros Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lexington, Massachusetts, US, 19.8M shares outstanding, ISIN US4923271013 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Keros Therapeutics Inc

$KROS

Health Care · Biotechnology

IR Run Scenarios

$11.95

+2.66%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Employees

Website

www.kerostx.com/

IPO

2020-04-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)